NCT05843305 - A Study of BPI-452080 in Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

March 25, 2025

Study Completion Date

October 31, 2025

Conditions

Solid TumorRenal Cell CarcinomaVon Hippel-Lindau Disease

Interventions

DRUG

BPI-452080

Subjects will receive BPI-452080 until disease progression

Trial Locations (5)

Fudan University Shanghai Cancer Center, Shanghai

Zhejiang Cancer Hospital, Hangzhou

Hunan Cancer Hospital, Hunan

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

West China Hospital of Sichuan University, Chengdu